<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Haloperidol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00502</strong>&#160; (APRD00538)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From <span class="caps">AMA</span> Drug Evaluations Annual, 1994, p279)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00502/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00502/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00502.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00502.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00502.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00502.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00502.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00502">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aloperidin</td><td>Janssen-Cilag</td></tr><tr><td>Bioperidolo</td><td>Firma</td></tr><tr><td>Brotopon</td><td>Pfizer</td></tr><tr><td>Dozic</td><td>Rosemont</td></tr><tr><td>Duraperidol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Einalon S</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Eukystol</td><td>Merckle</td></tr><tr><td>Haldol</td><td>Janssen-Cilag</td></tr><tr><td>Halosten</td><td>Shionogi Seiyaku</td></tr><tr><td>Keselan</td><td>Sumitomo</td></tr><tr><td>Linton</td><td>Tanabe Mitsubishi Pharma</td></tr><tr><td>Peluces</td><td>lsei</td></tr><tr><td>Serenace</td><td>Pfizer</td></tr><tr><td>Sigaperidol</td><td>Siegfried</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antipsychotic-agents">Antipsychotic Agents</a></li>
<li><a href="/mesh/butyrophenones">Butyrophenones</a></li>
<li><a href="/mesh/antidyskinetics">Antidyskinetics</a></li></ul></td></tr><tr><th>CAS number</th><td>52-86-8</td></tr><tr><th>Weight</th><td>Average: 375.864<br>Monoisotopic: 375.140134897</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>23</sub>ClFNO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>LNEPOXFFQSENCJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Piperidines</td></tr><tr><th>Subclass</th><td>Phenylpiperidines</td></tr><tr><th>Direct parent</th><td>Phenylpiperidines</td></tr><tr><th>Alternative parents</th><td>Butyrophenones; Acetophenones; Benzoyl Derivatives; Fluorobenzenes; Chlorobenzenes; Aryl Chlorides; Aryl Fluorides; Tertiary Alcohols; Tertiary Amines; Ketones; Enolates; Polyamines; Organofluorides; Organochlorides</td></tr><tr><th>Substituents</th><td>acetophenone; benzoyl; chlorobenzene; fluorobenzene; aryl fluoride; benzene; aryl chloride; aryl halide; tertiary alcohol; tertiary amine; ketone; enolate; polyamine; organochloride; carbonyl group; organohalogen; organofluoride; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioural problems in children with disrubtive behaviour disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of severe nausea and vomiting.</td></tr><tr><th>Pharmacodynamics</th><td>Haloperidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.</td></tr><tr><th>Mechanism of action</th><td>The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ.</td></tr><tr><th>Absorption</th><td>Oral-60%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>92%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Haloperidol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00103">4-(4-chlorophenyl)-4-hydroxypiperidine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/103">Details</a></td></tr><tr><td>Haloperidol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003074" target="_blank">Carbonyl reductase [NADPH] 1</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00104">Reduced haloperidol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/104">Details</a></td></tr><tr><td>Haloperidol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li></ul></td><td><a href="/metabolites/DBMET00105">Haloperidol glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/105">Details</a></td></tr><tr><td>Haloperidol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00106">Haloperidol 1,2,3,6-tetrahydropyridine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/106">Details</a></td></tr><tr><td>Haloperidol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li></ul></td><td><a href="/metabolites/DBMET00252">fluorobenzoylpropionic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/253">Details</a></td></tr><tr><td>Haloperidol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00333">4-(4-Chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HPP+)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/334">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00104">Reduced haloperidol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01211">Haloperidol reduced pyridinium ion derivative</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1357">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01211">Haloperidol reduced pyridinium ion derivative</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET01212">Haloperidol pyridinium ion derivative</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1358">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00106">Haloperidol 1,2,3,6-tetrahydropyridine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01212">Haloperidol pyridinium ion derivative</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1359">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3 weeks</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=165 mg/kg (rats, oral)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9465</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6023</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6673</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8563</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8137</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6058</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8355</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5796</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9207</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.9197</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9248</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6899</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7933</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8769
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.4367 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7474
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ortho mcneil pharmaceutical</li>
<li>Ortho mcneil pharmaceutical inc</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Lederle laboratories div american cyanamid co</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Par pharmaceutical inc</li>
<li>Purepac pharmaceutical co</li>
<li>Quantum pharmics ltd</li>
<li>Roxane laboratories inc</li>
<li>Royce laboratories inc</li>
<li>Sandoz inc</li>
<li>Scs pharmaceuticals</li>
<li>Vintage pharmaceuticals llc</li>
<li>Watson laboratories inc</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Ortho mcneil janssen pharmaceutical inc</li>
<li>App pharmaceuticals llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Claris lifesciences ltd</li>
<li>Hospira inc</li>
<li>Sandoz canada inc</li>
<li>Teva parenteral medicines inc</li>
<li>Alpharma uspd inc</li>
<li>Morton grove pharmaceuticals inc</li>
<li>Pharmaceutical assoc inc div beach products</li>
<li>Silarx pharmaceuticals inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Ortho mcneil janssen pharmaceuticals inc</li>
<li>Abraxis pharmaceutical products</li>
<li>Akorn strides llc</li>
<li>Gland pharma ltd</li>
<li>Marsam pharmaceuticals llc</li>
<li>Smith and nephew solopak div smith and nephew</li>
<li>Solopak medical products inc</li>
<li>Solopak laboratories inc</li>
<li>Actavis mid atlantic llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li>APPD</li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.bocapharmacal.com">Boca Pharmacal</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Coupler Enterprises Inc.</li>
<li>Dept Health Central Pharmacy</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li>McNeil Laboratories</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li>Novex Pharma</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li>OMJ Pharmaceuticals</li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho-McNeil-Janssen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Association</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.silarx.com">Silarx Pharmaceuticals</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>Superior Pharmeceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intramuscular</td><td></td></tr><tr><td>Liquid</td><td>Oral</td><td></td></tr><tr><td>Solution</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00517">Anisotropine Methylbromide</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine</td></tr><tr><td><a href="/drugs/DB00572">Atropine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00245">Benzatropine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00810">Biperiden</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00771">Clidinium</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Clozapine, a moderate CYP2D6 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive CNS despresant and anticholinergic effects may also occur. Monitor for changes in the therapeutic and adverse effects of haloperidol if clozapine is initiated, discontinued or dose changed. Also monitor for increased CNS depressant and anticholinergic effects during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00804">Dicyclomine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00392">Ethopropazine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the effect and toxicity of haloperidol.</td></tr><tr><td><a href="/drugs/DB08909">Glycerol Phenylbutyrate</a></td><td>Haloperidol may induce hyperammonemia. Monitor ammonia levels closely when use of haloperidol is necessary in UCD patients.</td></tr><tr><td><a href="/drugs/DB00986">Glycopyrrolate</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Haloperidol may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB00725">Homatropine Methylbromide</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00424">Hyoscyamine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. </td></tr><tr><td><a href="/drugs/DB01625">Isopropamide</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the effect and toxicity of haloperidol.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the effect and toxicity of haloperidol.</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Possible extrapyramidal effects and neurotoxicity with this combination</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB04843">Mepenzolate</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00940">Methantheline</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Methyldopa increases haloperidol effect or risk of psychosis</td></tr><tr><td><a href="/drugs/DB01173">Orphenadrine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00383">Oxyphencyclimine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00387">Procyclidine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00782">Propantheline</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>The rifamycin decreases the effect of haloperidol</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The rifamycin decreases the effect of haloperidol</td></tr><tr><td><a href="/drugs/DB00747">Scopolamine</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Haloperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Haloperidol, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Haloperidol is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Haloperidol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Haloperidol if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Haloperidol. Consider alternate therapy or monitor for therapeutic/adverse effects of Haloperidol if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Haloperidol may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00505">Tridihexethyl</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00376">Trihexyphenidyl</a></td><td>The anticholinergic increases the risk of psychosis and tardive dyskinesia</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of haloperidol if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.</li></ul></td></tr></tbody></table>